Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma
Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Glaucoma is the leading cause of irreversible blindness worldwide. Previous studies demonstrate that smaller eye drops used in the treatment of glaucoma are just as efficacious as their larger counterparts. The proposed study hopes to demonstrate the non-inferiority of using Nanodropper to lower intraoccular pressure (IOP) in glaucoma patients compared to standard of care eye drops.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• 18 years old or older
• Diagnosis of open-angle glaucoma (OAG) or ocular hypertension (OHT)
• Use of prostaglandin analogue (PGA) eye drop
• Stable disease status (no visual field loss progression or increase in IOP-lowering medications in the last 6 months)
Locations
United States
California
University of California, San Francisco
RECRUITING
San Francisco
Contact Information
Primary
Mari Costantini
Mari.Costantini@ucsf.edu
415-353-2289
Time Frame
Start Date: 2022-10-10
Estimated Completion Date: 2024-12-10
Participants
Target number of participants: 40
Treatments
Experimental: Nanodropper
Participants will receive the Nanodropper with instructions and attend clinic visits at baseline, 1, and 3 months. Participants will administer their eye drops using the Nanodropper.
No_intervention: Standard of Care Dropper
Participants will receive standard of care eye dropper with instructions and attend clinic visits at baseline, 1, and 3 months. Participants will administer their eye drops using the standard of care eye dropper.
Related Therapeutic Areas
Sponsors
Leads: University of California, San Francisco
Collaborators: Icare Finland Oy, Nanodropper, Inc.